64th ASH Annual Meeting and Exposition: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities I

Symposia: Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities Oral and Poster Abstracts
Oral

Research, Sickle Cell Disease, Biological therapies, adult, Acute Myeloid Malignancies, AML, MDS, clinical trials, Bone Marrow Failure Syndromes, Clinical Practice (Health Services and Quality), Aplastic Anemia, Clinical Research, Hemoglobinopathies, Chronic Myeloid Malignancies, pediatric, Diseases, Therapies, Lymphoid Malignancies, Adverse Events, registries, Myeloid Malignancies, Study Population, Human, Transplantation

260-262 (Ernest N. Morial Convention Center)

Moderators:

Joseph Maakaron, MD, University of Minnesota and Filippo Milano, MD, Fred Hutchinson Cancer Center

Disclosures:

Maakaron: ADC Therapeutics: Research Funding; Gilead: Research Funding; CRISPR Therapeutics: Research Funding; Precision Biosciences: Research Funding.

4:30 PM

985

Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS

Raynier Devillier^1,2,3^*, Edouard Forcade, MD, PhD⁴, Jacques-Olivier Bay, MD, PhD^5,6, Anne Huynh⁷^*, Anna Berceanu, MD⁸^*, Regis Peffault De Latour⁹^*, Claude-Eric Bulabois, MD¹⁰^*, Mohamad Mohty, MD PhD¹¹, Michael Loschi, MD, PhD¹²^*, Emmanuelle Tavernier, MD¹³^*, Micha Srour¹⁴^*, Patrice Chevallier, MD¹⁵, Amandine Charbonnier, MD¹⁶^*, Aline Schmidt¹⁷^* and Didier Blaise, MD, PhD¹⁸

¹Hematology Department, Institut Paoli-Calmettes, Marseille, France
²Aix Marseille University, Medicine Faculty, Marseille, France
³CRCM / INSERM U1068, Marseille, France
⁴Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Hôpital Haut-Leveque, Bordeaux, France
⁵University of Auvergne, EA7453, CIC501, Clermont-Ferrand, France
⁶CHU de Clermont-Ferrand, Site Estaing, Service de thérapie cellulaire et d'hématologie clinique adulte, Clermont-Ferrand, France
⁷Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
⁸Clinical Hematology, Besançon University Hospital, Besançon, France
⁹Hematology and Transplantation Unit, Hôpital Saint Louis, AP-HP, Paris, France
¹⁰Service d'Hématologie, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France
¹¹EBMT Paris study office / CEREST-TC, Paris, France, Department of Hematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Sorbonne University, Paris, France
¹²Hematology department, CHU de Nice, Universite Cote d'Azur, Nice, France
¹³Hematology Department, Oncology institute of Loire, Saint Priest en Jarez, France
¹⁴Hematology, University hospital of Lille, Lille, FRA
¹⁵Hematology Department, Nantes University Hospital, Nantes, France
¹⁶Service d’Hématologie Clinique et Thérapie cellulaire, Centre Hospitalier Universitaire d’Amiens, Amiens, France
¹⁷Clinical Hematology, Angers University Hospital, Angers, France
¹⁸Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France

4:45 PM

986

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)

Adetola A. Kassim, MBBS, MS^1,2, Karina Wilkerson, MSN, NP³^*, Josu de la Fuente, PhD^4,5, Adriana Seber, MD, MS^6,7,8, Roseane V Gouveia⁹^*, Carmem Bonfim, MD, PhD^10,11,12^*, Belinda Pinto Simões, MD, PhD^13,14,15^*, Erfan Nur, MD, PhD¹⁶, Biljana N. Horn, MD^17,18,19, Michael Eckrich, MD, MPH²⁰, Rabi Hanna, MD^21,22, Nathalie Dhedin, MD^23,24^*, Fahed Almhareb, MBBS, FACP²⁵, Mahmoud Aljurf, MD²⁵, Hemalatha G. Rangarajan, MD²⁶, Katie S. Gatwood, PharmD²⁷^*, James P Connelly, MD²⁸^*, Mohsen Alzahrani, MD^29,30,31^*, Ali Alahmari, MD²⁵^*, Mark Rodeghier, PhD³²^* and Michael R. DeBaun, MD, MPH³³

¹Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Vanderbilt University School of Medicine, Nashville, TN
²Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
³Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
⁴Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
⁵Imperial College Healthcare NHS Trust, St Mary's Hospital, London, United Kingdom
⁶Pediatric Hematopoietic Stem Cell Transplantation, Pediatric Oncology Institute - Graacc - Unifesp, Sao Paulo, Brazil
⁷Hospital Samaritano, Sao Paulo, SP, Brazil
⁸Hospital Samaritano, São Paulo, Brazil
⁹Hospital Sao Camilo Pompeia, Pediatric Oncology and Hematopoietic Cell Transplantation, São Paulo, Brazil
¹⁰Bone Marrow Transplantation unit, Federal University of Parana, Curitiba, PR, Brazil
¹¹Instituto de Pesquisa Pele Pequeno Príncipe/Hospital Infantil Pequeno Principe, Curitiba, Brazil
¹²Pediatric Blood and Marrow Transplantation Program, Federal University of Parana, Curitiba, PR, Brazil
¹³Center for Cell-Based Therapy, Hemotherapy Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
¹⁴Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, Brazil
¹⁵Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil., Ribeirão Preto, Brazil
¹⁶Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands
¹⁷UF Health Shands Children’s Hospital, Gainesville, FL
¹⁸UCSF, Gainesville, FL
¹⁹Department of Pediatrics, University of Florida, Gainesville, FL
²⁰Levine Children's Hospital At Carolinas Medical Center, Charlotte, NC
²¹Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²²Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Cleveland Clinic Foundation, Cleveland, OH
²³St-Louis Hospital, APHP, Paris Cedex 10, FRA
²⁴St-Louis Hospital, APHP, Adolescents and Young Adults Hematology Department, Paris, France
²⁵Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
²⁶Division of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Childrens Hospital, Columbus, OH
²⁷Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN
²⁸Department of Pediatrics, Division of Pediatric Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN
²⁹King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
³⁰College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
³¹Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia
³²Statistical Consultant, Rodeghier Consultants, Chicago, IL
³³Department of Pediatrics, Division of Hematology & Oncology, Vanderbilt University School of Medicine, Nashville, TN

5:00 PM

987

Efficacy and Safety of a Novel Non-Myeloablative Conditioning Regimen for Hematopoietic Cell Transplantation in Adults with Severe Aplastic Anemia

Rachel M Gilmore, PharmD¹^*, Karin M Abernathy, PharmD²^*, Kendall C Shultes, PharmD³^*, Dwight D Eplin, PharmD³^*, Lindsay Orton, PharmD⁴^*, Adetola A. Kassim, MBBS, MS⁵, Bipin N. Savani, MD⁶, Salyka M. Sengsayadeth, MD^6,7^*, Brian G. Engelhardt, MD^6,8,9, Wichai Chinratanalab, MD⁶, TaeKon Kim, MD^10,11, Bhagirathbhai Dholaria, MBBS^{6,12,13,14,15}, Reena Jayani, MD^4,6, Leena Choi, PhD¹⁶^*, Elizabeth McNeer, MS¹⁶^* and Katie S. Gatwood, PharmD¹⁷^*

¹Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN
²Sarah Cannon Cancer Center, Nashville, TN
³VA Tennessee Valley Healthcare System, Nashville, TN
⁴Vanderbilt University Medical Center, Nashville, TN
⁵Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN
⁶Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN
⁷Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
⁸Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
⁹Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Brentwood, TN
¹⁰Division of hematology/oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
¹¹Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
¹²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
¹³Vanderbilt University Medical Center and Vanderbilt- Ingram Cancer Center, Nashville, TN
¹⁴Division of Hematology/Oncology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN
¹⁵Vanderbilt University Medical center, Nashville, TN, USA, Nashville, TN
¹⁶Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
¹⁷Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN

5:15 PM

988

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Alexandros Spyridonidis¹^*, Myriam Labopin, MD²^*, Tobias Gedde-Dahl, MD³^*, Arnold Ganser, MD⁴^*, Matthias Stelljes, MD⁵^*, Charles Craddock^6,7, Eva Maria Wagner, MD⁸, Jurjen Versluis, MD, PhD⁹^*, Thomas Schroeder¹⁰, Igor Wolfgang Blau, MD^11,12^*, Gerald Wulf, MD¹³^*, Peter Dreger, MD¹⁴^*, Gitte Olesen¹⁵^*, Henrik Sengeloev¹⁶^*, Nicolaus Kröger, MD¹⁷^*, Victoria Potter, MBBS, BSc, FRACP, FRCPA¹⁸^*, Edouard Forcade, MD, PhD¹⁹, Jakob Passweg, MD²⁰^*, Regis Peffault De Latour²¹^*, Johan Maertens²²^*, Keith Wilson, FRCPath, MRCP, MBBS²³^*, Jean-Henri Bourhis, MD²⁴^*, Bipin Savani, MD²⁵, Fabio Ciceri, MD²⁶^*, Arnon Nagler, MD²⁷ and Mohamad Mohty, MD PhD²⁸

¹Hematology Stem Cell Transplant Unit, School of Medicine, University of Patras, PATRA, Greece
²Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
³Rikshospitalet, Clinic for Cancer Medicine, Hematology Dept., Section for Stem Cell Transplantation, Oslo University Hospital, Oslo, Norway
⁴Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany
⁵University Hospital of Muenster, Muenster, Germany
⁶Department of Haematology, University Hospital Birmingham NHS Trust, Queen Elizabeth Medical Centre, Birmingham, ENG, United Kingdom
⁷Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
⁸Department of Haematology, Oncology and Pneumology, University Medical Center Mainz, Mainz, Germany
⁹Erasmus University Medical Center Cancer Institute, Rotterdam, Rotterdam, Netherlands
¹⁰Dept. of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany
¹¹Department of BMT, Clinic of Hematology, Oncology and Tumorimmunology, University Medicine Berlin, Berlin, Germany
¹²Dept. Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Berlin, Germany
¹³University Medicine Göttingen, Hematology and Medical Oncology, Goettingen, Germany
¹⁴Department of Medicine V, University of Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany
¹⁵Aarhus University Hospital, Aarhus, DNK
¹⁶Rigshospitalet, Copenhagen, Denmark
¹⁷University Medical Center Hamburg-Eppendorf, Department of Stem Cell Transplantation, Hamburg, Germany
¹⁸King's College Hospital NHS Foundation Trust, London, United Kingdom
¹⁹Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Hôpital Haut-Leveque, Bordeaux, France
²⁰University Hospital, Hematology, Basel, Switzerland, Basel, Switzerland
²¹Assistance Publique–Hôpitaux de Paris, Saint-Louis Hospital, Université Paris Cité, Paris, France
²²University Hospital Gasthuisberg, Leuven, Belgium
²³University Hospital of Wales, Cardiff, United Kingdom
²⁴BMT Service, Department of Hematology, Institut Gustave Roussy, Villejuif, France
²⁵Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
²⁶Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
²⁷Hematology and Bone Marrow Transplant Unit, Chaim Sheba Medical Center, Tel Hashomer, Israel
²⁸Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France, Paris, France

5:30 PM

989

Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Li Xuan¹^*, Min Dai¹^*, Erlie Jiang, PhD²^*, Yu Wang³^*, Fen Huang¹^*, Zhiping Fan¹^*, Na Xu¹^*, Danian Nie⁴^*, Xinquan Liang⁵^*, Hong Chen⁶^*, Jieyu Ye¹^*, Pengcheng Shi¹^*, Hui Liu¹^*, Hua Jin¹^*, Ren Lin¹^*, Chenhua Yan³^*, Yu Zhang¹^*, Jing Sun¹^*, Mingzhe Han²^* and Qifa Liu, MD¹

¹Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
²Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
³Institute of Hematology, Peking University People’s Hospital, Beijing, China
⁴Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
⁵Department of Hematology, First People’s Hospital of Chenzhou, Chenzhou, China
⁶Department of Hematology, Southern Medical University Nanfang Hospital, Guangzhou, China

5:45 PM

990

Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Kimimori Kamijo, MD¹^*, Yoshimitsu Shimomura, MD^2,3^*, Sung-Won Kim, MD, PhD⁴^*, Takahide Ara, M.D., Ph.D.⁵^*, Jun Ishikawa⁶^*, Tetsuya Eto, MD, PhD⁷^*, Nobuhiro Hiramoto, MD⁸^*, Ishikazu Mizuno, MD⁹^*, Shigeru Kusumoto, MD, PhD¹⁰, Yasunori Ueda¹¹, Ken-ichi Matsuoka, MD, PhD¹², Makoto Onizuka, MD, PhD¹³, Takahiro Fukuda⁴^*, Yoshiko Atsuta^14,15^* and Eisei Kondo¹⁶^*

¹Rinku General Medical Center, Izumisano, Japan
²Department of Haematology, Kobe City Medical Center General Hospital, Kobe, Japan
³Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Osaka, Japan
⁴Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
⁵Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
⁶Osaka International Cancer Institute, Osaka, Japan
⁷Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
⁸Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan
⁹Department of Hematology, Hyogo Cancer Center, Akashi, Japan
¹⁰Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
¹¹Department of Haematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan
¹²Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan
¹³Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
¹⁴Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan
¹⁵Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan
¹⁶Kawasaki Medical School, Kurashiki, OKA, Japan

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

721.O1.6 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities I